Aptose delays Hanmi acquisition closing to June 2026 on pending Korean regulatory approvals

Aptose Biosciences Inc.

Closing of plan of arrangement with Hanmi delayed to June 2026 as Korean regulatory approvals remain in progress; parties expect closing to occur.
Shareholders to receive C$2.41 per share (28% premium over 30-day VWAP on the TSX) upon completion.
Aptose received additional US$2.0M advance under US$11.9M loan facility from Hanmi, total draws now US$9.9M; final US$2.0M expected shortly.
Advances support uninterrupted continuation of TUSCANY clinical trial for tuspetinib in frontline AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.